Tygacil Adverse Reactions

Expected frequency of adverse reactions is presented in CIOMS frequency categories: Very common ≥10%; Common ≥1% and <10%; Uncommon ≥0.1% and <1%; Rare ≥0.01% and <0.1%; Very rare <0.01%; Frequency not known cannot be estimated from the available data.
For patients who received tigecycline, the following adverse reactions were reported: (See Table 9.)

Click on icon to see table/diagram/image

In a pooled analysis of all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4.0% (150/3788) of subjects receiving tigecycline and 3.0% (110/3646) of subjects receiving comparator drugs. In a pooled analysis of these trials, the risk difference of all-cause mortality was 0.9% (95% CI 0.1, 1.8) between tigecycline and comparator-treated subjects. In a pooled analysis of these trials, based on a random effects model by trial weight, an adjusted risk difference of all-cause mortality was 0.6% (95% CI 0.1, 1.2) between tigecycline-treated and comparator-treated subjects. No significant differences were observed between tigecycline and comparators within each infection type (see Table 10). The cause of the imbalance has not been established. Generally, deaths were the result of worsening or complications of infection or underlying co-morbidities. (See Table 10.)

Click on icon to see table/diagram/image

The most common treatment-emergent adverse reactions in subjects treated with tigecycline were nausea 29.9% (19.3% mild; 9.2% moderate; 1.4% severe) and vomiting 19.9% (12.1% mild; 6.8% moderate; 1.1% severe). In general, nausea or vomiting occurred early (Days 1-2).
Discontinuation from tigecycline was most frequently associated with nausea (1.6%) and vomiting (1.3%).